EGFR and non-small cell lung carcinoma: Studies show that EFGR‐TKI treatment, such as erlotinib and gefitinib, can prolong the median progression‐free survival of 8‐16 months in the EGFR‐mutant NSCLC patients, but then, the EGFR‐TKI resistance may develop 16.